This document summarizes information about chronic kidney disease (CKD) and vascular access solutions. Over 2 million people globally have end-stage kidney disease (ESKD) and require dialysis or kidney transplantation. Hemodialysis often relies on arteriovenous fistulas (AVFs) or grafts (AVGs) for vascular access, but many fail due to stenosis. Sirolimus is being studied as a resorbable coating to prevent stenosis and improve AVF/AVG outcomes. The document outlines clinical trial results showing Sirolimus improved AVF maturation rates and reduced abandonment. An ongoing Phase 3 trial is evaluating Sirolimus for AVFs. The results indicate Sirolimus has the potential to significantly improve vascular access outcomes